

**Press Release**

**Frankfurt am Main; 23.08.2019**

**REVERT Project: Precision medicine for colorectal cancer patients: GenXPro technology for improved diagnostics and treatment**  
About 150,000 patients die every year from colorectal cancer in Europe. In particular patients in the late stage of the disease often only have a life expectancy of 12 months after the diagnosis. Chemotherapy can substantially extend the life span. However, the prerequisite is that the individual cancer of the patient responds to the treatment. Unfortunately, it is currently not possible for the doctor to identify in advance which patient benefits from the treatment and who suffers from the sometimes considerable side effects of the therapy without the cancer being stopped.  
This situation, which is unsatisfactory for both patients and physicians, is set to be significantly improved by the REVERT research project, which will receive a total of 6 million euros from the European Union. Led by the leading biobank IRCCS San Raffaele Pisana in Rome, 14 leading clinical and industrial partners from 6 European countries will combine the latest molecular biology techniques with artificial intelligence to identify those patients for whom the therapy is likely to be effective. GenXPro GmbH will be responsible for the molecular genetic characterization of the tumors. "I am proud and satisfied that our partners have chosen our technology," says Dr. Peter Winter, Managing Director of GenXPro. " it's about time that the significant technical advances that science but also we at GenXPro have made as a company over the last few years come to patients," adds Björn Rotter, GenXPro's research director. And "The REVERT project is an important step towards the overdue personalization of cancer therapy"  
GenXPro GmbH, based at the Frankfurt Innovation Center (FIZ) Biotechnology, uses the latest high-throughput analysis techniques for DNA and RNA in combination with modern big-data IT methods for all areas of the life sciences and since more than 10 years with one strong focus on oncology. GenXPro holds an important patent for the correction of high-throughput sequencing data. The company received the Innovation Award of the International Congress for Personalized Medicine, PerMediCon, in Cologne in December 2016 and was named the best European service provider for bioinformatics and sequencing services in 2019 by the online pharmaceutical platform Global Health and Pharma (GHP).